Acute myeloid leukemia Press Release

  • Calling pr ads
  • Calling pr ads
Title Picture
12/11/2017 - 14:37
Study identifies agent that can reverse resistance to targeted drug in some leukemia cell types
Dana Farber's picture
Dana Farber
12/11/2017 - 07:27
Roswell Park Hematology Experts Sharing New Research in ASH 2017 Podium Presentations
Roswell Park Cancer Institute's picture
Roswell Park Ca...
12/07/2017 - 13:23
Dr. Mohamad Cherry of Atlantic Hematology Oncology to Lead Meeting Session and Help Present Multiple Studies at Top International Blood Cancer Meeting
Atlantic Health System's picture
Atlantic Health...
12/05/2017 - 08:02
BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY
Biolinerx's picture
Biolinerx
12/04/2017 - 07:21
BioLineRx Reports Overall Survival Results from Long-Term Follow-Up of Phase 2a Trial in r/r AML
Biolinerx's picture
Biolinerx
11/06/2017 - 17:36
FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN
Cellectis's picture
Cellectis
11/02/2017 - 07:36
Preclinical data demonstrate that BL-8040 mobilizes a significant number of these HSCs compared to G-CSF, thus potentially improving graft quality
Biolinerx's picture
Biolinerx
10/10/2017 - 17:36
Hope for Elderly Leukemia Patients
Roswell Park Cancer Institute's picture
Roswell Park Ca...
10/05/2017 - 17:14
A new CRISPR-engineered cancer model to test therapeutics
Broad Institute's picture
Broad Institute
09/26/2017 - 01:27
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration
Biolinerx's picture
Biolinerx
09/14/2017 - 17:14
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
Daiichi Sankyo's picture
Daiichi Sankyo
09/12/2017 - 21:40
Advancing the Hematology Field
Celgene's picture
Celgene
09/05/2017 - 07:43
MEI Pharma Reports Fiscal Year 2017 Results
MEI Pharma's picture
MEI Pharma
09/04/2017 - 09:17
Cellectis Reports Clinical Hold of UCART123 Studies
Cellectis's picture
Cellectis
09/01/2017 - 11:15
Pfizer Receives FDA Approval for MYLOTARG (gemtuzumab ozogamicin)
Pfizer's picture
Pfizer
09/01/2017 - 08:34
FDA approves Mylotarg for treatment of acute myeloid leukemia
Food and Drug Administration's picture
FDA
09/01/2017 - 01:14
Tracing Blood Cancer Family Tree
Celgene's picture
Celgene
08/07/2017 - 17:14
Fujifilm initiates a Phase I clinical trial of Anti-Cancer Drug FF-10101 in the United States in patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Fujifilm's picture
Fujifilm
08/03/2017 - 11:05
FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia
Food and Drug Administration's picture
FDA
08/02/2017 - 04:17
Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
MEI Pharma's picture
MEI Pharma
08/01/2017 - 12:41
FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia
Food and Drug Administration's picture
FDA
08/01/2017 - 11:42
FDA Grants Approval of IDHIFA, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation
Celgene's picture
Celgene
07/17/2017 - 08:33
ASH Selects 11 Fellows for Research Award to Support Careers in Academic Hematology
American Society of Hematology's picture
American Societ...
07/13/2017 - 05:57
American Society of Hematology Selects 31 Medical Students and Residents for 2017 HONORS Award
American Society of Hematology's picture
American Societ...
07/11/2017 - 16:03
FDA Advisory Committee Votes in Favor of Pfizers MYLOTARG (gemtuzumab ozogamicin) for Acute Myeloid Leukemia
Pfizer's picture
Pfizer
07/04/2017 - 06:10
DFG Approves Seven New Research Units and One New Clinical Research Unit
Deutsche Forschungsgemeinschaft's picture
Deutsche Forsch...
06/30/2017 - 07:27
BESPONSA Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Pfizer's picture
Pfizer
06/26/2017 - 20:04
First in Human Administration of UCART123 in Cellectis AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital
Cellectis's picture
Cellectis
06/23/2017 - 07:59
NEJM publishes full analysis of Rydapt (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
Novartis's picture
Novartis
06/21/2017 - 17:06
New Antibody Uses One-Two Punch to Potentially Treat Blood Cancers
American Society of Hematology's picture
American Societ...
06/19/2017 - 11:55
New Markers Found for Acute Myeloid Leukemia
Sapienza University 's picture
SapienzaUniv
06/14/2017 - 06:08
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
MEI Pharma's picture
MEI Pharma
06/12/2017 - 12:54
Beat AML clinical trial for leukemia is launched
UT Southwestern Medical Center's picture
UTSouthwestern
06/06/2017 - 11:50
Personalizing AML Treatment Through Mutational Profiling
Celgene's picture
Celgene
06/06/2017 - 10:37
Precision Therapy Enasidenib Effective in Treating Deadly Form of Leukemia
American Society of Hematology's picture
American Societ...
06/06/2017 - 09:00
Updated Data from Phase 1 Trial of Oral IDHIFA (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation
Celgene's picture
Celgene
06/05/2017 - 12:35
Four Dana-Farber researchers awarded prestigious 'outstanding investigator awards' by National Cancer Institute
Dana Farber's picture
Dana Farber
06/05/2017 - 04:52
Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
MEI Pharma's picture
MEI Pharma
05/23/2017 - 09:04
Study leads to breakthrough in better understanding acute myeloid leukaemia
University of Birmingham's picture
University of B...
05/22/2017 - 03:58
BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML
Biolinerx's picture
Biolinerx
05/18/2017 - 07:37
Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
MEI Pharma's picture
MEI Pharma
05/03/2017 - 07:58
RYDAPT (midostaurin) Approved for the Treatment of FLT3-Mutated Acute Myeloid Leukemia, available for order at Biologics, Inc.
McKesson's picture
McKesson
04/28/2017 - 13:27
Backed by Dana-Farber research, FDA approves new AML drug
Dana Farber's picture
Dana Farber
04/28/2017 - 06:01
FDA approves new combination treatment for acute myeloid leukemia
Food and Drug Administration's picture
FDA
04/25/2017 - 10:10
New drug compounds could provide non-toxic, effective way to inhibit enzymes that cause cancers
Purdue University's picture
Purdue
04/24/2017 - 16:45
Biologics, Inc. Selected by TESARO as a Specialty Pharmacy Provider for ZEJULATM (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer
McKesson's picture
McKesson
04/21/2017 - 12:52
Pfizer Receives Positive CHMP Opinion for BESPONSA (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Pfizer's picture
Pfizer
04/12/2017 - 03:59
Argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients
FlandersBio's picture
FlandersBio
04/05/2017 - 05:32
Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting
Geron's picture
Geron
03/23/2017 - 07:09
Medidata's Clinical Technology Platform Selected for Groundbreaking "Beat AML Master Trial"
Medidata's picture
Medidata
03/07/2017 - 03:44
New drug combination targets aggressive blood cancer
Van Andel's picture
Van Andel
02/22/2017 - 13:55
Specialty Physician Groups Publish Guideline to Improve Care for Acute Leukemia Patients
American Society of Hematology's picture
American Societ...
02/06/2017 - 17:23
FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S.
Cellectis's picture
Cellectis
01/03/2017 - 12:23
Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN
Cellectis's picture
Cellectis
12/29/2016 - 06:53
Possible Treatment Targets Found for Pre-Malignant Bone Marrow Disorders
Cincinnati Children's Hospital Medical Center's picture
Cincinnati Childrens
12/15/2016 - 18:45
Cellectis Announces Recombinant DNA Advisory Committees (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN
Cellectis's picture
Cellectis
12/12/2016 - 10:39
Fasting kills cancer cells of most common type of childhood leukemia
UT Southwestern Medical Center's picture
UTSouthwestern
12/07/2016 - 18:12
Personalized Cancer Vaccine is Associated with Promising Outcomes for Patients with Acute Myeloid Leukemia
Dana Farber's picture
Dana Farber
12/06/2016 - 13:03
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
Geron's picture
Geron
12/05/2016 - 09:25
Combined Analysis of Oral Epigenetic Therapy, CC-486, Demonstrated Hematologic Responses in Patients Who Received Prior Epigenetic Hypo-Methylating Agents (HMA)
Celgene's picture
Celgene